This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Major, A. S. Articles by Fazio, S. Search for Related Content PubMed PubMed Citation Articles by Major, A. S. Articles by Fazio, S. Related Collections Lipids Pathophysiology Gene expression Genetically altered mice Gene therapy

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1790.)
© 2001 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Increased Cholesterol Efflux in Apolipoprotein AI (ApoAI)–Producing Macrophages as a Mechanism for Reduced Atherosclerosis in ApoAI^(-/-) Mice

Amy S. Major; Dwayne E. Dove; Hiroyuki Ishiguro; Yan Ru Su; Abigail M. Brown; Lily Liu; Kathy J. Carter; MacRae F. Linton; Sergio Fazio

From the Departments of Medicine (A.S.M., H.I., Y.R.S., A.M.B., L.L., K.J.C., M.F.L., S.F.), Pharmacology (M.F.L.), and Pathology (D.E.D., S.F.), Vanderbilt University School of Medicine, Nashville, Tenn.

Correspondence to Drs Sergio Fazio or MacRae F. Linton, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 315 Medical Research Building II, Nashville, TN 37232-6300. E-mail sergio.fazio{at}mcmail.vanderbilt.edu or macrae.linton@mcmail.vanderbilt.edu

Abstract—— The concentration of apolipoprotein (apo) AI in the artery wall is thought to enhance cellular cholesterol efflux and protect against atherosclerosis. It has been shown that although macrophages do not make apoAI, they respond to it by increased cholesterol efflux. We hypothesized that macrophage production of apoAI would increase cholesterol efflux and reduce atherogenesis. In this study, we produced mice expressing human apoAI under the control of the macrophage-specific scavenger receptor-A promoter (m-AI). Human apoAI was detectable in the serum HDL fraction of m-AI transgenic mice at concentrations too low to affect serum cholesterol or HDL levels. Immunoblotting showed the presence of human apoAI in transgenic macrophage culture supernatants, mostly as lipoprotein-free protein, with a small component associated with HDL-like particles. Atherosclerosis studies using apoAI^(-/-) mice transplanted with m-AI bone marrow showed that in the absence of macrophage-derived apoE, local expression of apoAI reduced diet-induced lesions in the proximal aorta. Additionally, m-AI macrophages showed a 40% increase in cholesterol efflux compared with control macrophages. These data support the hypothesis that apoAI production by macrophages in the artery wall is protective against atherosclerosis. This protection is likely mediated by increased cholesterol efflux and decreased foam cell formation in vivo.

Key Words: apoAI • transgenic mice • macrophage • foam cell

This article has been cited by other articles:

				N. Mukhamedova, G. Escher, W. D'Souza, U. Tchoua, A. Grant, Z. Krozowski, M. Bukrinsky, and D. Sviridov Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo J. Lipid Res., November 1, 2008; 49(11): 2312 - 2322. [Abstract] [Full Text] [PDF]

				Y. R. Su, J. L. Blakemore, Y. Zhang, M. F. Linton, and S. Fazio Lentiviral Transduction of ApoAI Into Hematopoietic Progenitor Cells and Macrophages: Applications to Cell Therapy of Atherosclerosis Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1439 - 1446. [Abstract] [Full Text] [PDF]

				R. D. Atkinson, K. R. Coenen, M. R. Plummer, M. L. Gruen, and A. H. Hasty Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E284 - E290. [Abstract] [Full Text] [PDF]

				L. Wang, B. G. Sharifi, T. Pan, L. Song, A. Yukht, and P. K. Shah Bone Marrow Transplantation Shows Superior Atheroprotective Effects of Gene Therapy With Apolipoprotein A-I Milano Compared With Wild-Type Apolipoprotein A-I in Hyperlipidemic Mice J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1459 - 1468. [Abstract] [Full Text] [PDF]

				J. F. Oram and J. W. Heinecke ATP-Binding Cassette Transporter A1: A Cell Cholesterol Exporter That Protects Against Cardiovascular Disease Physiol Rev, October 1, 2005; 85(4): 1343 - 1372. [Abstract] [Full Text] [PDF]

				M. L. Gruen, M. R. Plummer, W. Zhang, K. A. Posey, M. Linton, S. Fazio, and A. H. Hasty Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I J. Lipid Res., September 1, 2005; 46(9): 2007 - 2014. [Abstract] [Full Text] [PDF]

				A. H. Hasty, M. R. Plummer, K. H. Weisgraber, M. F. Linton, S. Fazio, and L. L. Swift The recycling of apolipoprotein E in macrophages: influence of HDL and apolipoprotein A-I J. Lipid Res., July 1, 2005; 46(7): 1433 - 1439. [Abstract] [Full Text] [PDF]

				D. E. Dove, Y. R. Su, W. Zhang, W. G. Jerome, L. L. Swift, M. F. Linton, and S. Fazio ACAT1 Deficiency Disrupts Cholesterol Efflux and Alters Cellular Morphology in Macrophages Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 128 - 134. [Abstract] [Full Text] [PDF]

				K. S. Meir and E. Leitersdorf Atherosclerosis in the Apolipoprotein E-Deficient Mouse: A Decade of Progress Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1006 - 1014. [Abstract] [Full Text] [PDF]

				Y. Fu, A. Hoang, G. Escher, R. G. Parton, Z. Krozowski, and D. Sviridov Expression of Caveolin-1 Enhances Cholesterol Efflux in Hepatic Cells J. Biol. Chem., April 2, 2004; 279(14): 14140 - 14146. [Abstract] [Full Text] [PDF]

				A. M. Gotto Jr and E. A. Brinton Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update J. Am. Coll. Cardiol., March 3, 2004; 43(5): 717 - 724. [Abstract] [Full Text] [PDF]

				S. Fazio and M. F. Linton Apolipoprotein AI as Therapy for Atherosclerosis: Does the Future of Preventive Cardiology Include Weekly Injections of the HDL Protein? Mol. Interv., December 1, 2003; 3(8): 436 - 440. [Abstract] [Full Text] [PDF]

				S. Fazio, V. R. Babaev, M. E. Burleigh, A. S. Major, A. H. Hasty, and M. F. Linton Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice J. Lipid Res., October 1, 2002; 43(10): 1602 - 1609. [Abstract] [Full Text] [PDF]

				J. D. Smith An A+ for Macrophages in Reducing Atherosclerosis? Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1710 - 1711. [Full Text] [PDF]